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INTRODUCTION     
 
Melanocytes 
Our body is constantly under threat from external hazards. Skin, the 
main protection against many such environmental insults, is 
composed of 3 layers: the epidermis, dermis, and subcutaneous 
tissue. The main specialized cell types of the outermost layer, the 
epidermis, are the keratinocyte, the Langerhans cell, and the 
melanocyte. The melanocyte contains a unique organelle, the 
melanosome, that produces the pigment, melanin, to provide 
photoprotection against hazardous ultraviolet radiation (UVR). 
Melanocytes are small and nucleated cells that derive 
embryologically from melanoblasts, cells residing in the neural crest, 
that from the third to the sixth month of embryonic life colonize 
various districts of the body (epidermis, hair follicles and ocular 
uvea). At the skin level, melanoblasts are established in the Basal 
Lamina, the layer between the dermis 
and epidermis. Only reaching the right 
place, melanoblasts can undergo 
maturation and differentiation in the 
form of melanocytes beginning the 
synthesis of melanin.  
The skin melanocytes (Fig. 1), are 
equipped with dendritic extensions, 
through which they can transfer the 
melanin via exocytosis of 
melanosomes to the surrounding 
keratinocytes, the most represented 
 
Figure 1. Dendritic extension 
permits to melanocytes to transfer 
melanin to the sorrounding cells. 
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cells in the epidermal layer. 
The biochemical process leading to the production of melanin is 
called melanogenesis. This process is highly regulated by the 
interaction with keratinocytes. In response to UV radiation, 
keratinocytes secrete factors regulating the differentiation and 
homeostasis of pigmented cells, controlling also their survival, 
proliferation and motility. 
One of the key enzymes of the melanogenesis is the Tyrosinase. This 
protein mediates the conversion from tyrosine to DOPA-quinone, the 
limiting step for the production of melanin. For this reason tyrosinase 
regulation takes place at different levels; transcriptionally, 
translationally, post-translationally, by its degradation and retention 
in the endoplasmic reticulum (Ebanks et al., 2009). The 
dysregulation of any of these processes may cause in humans a 
number of dysfunctions related to pigmentation, such as albinism. In 
such dysfunction, the absence of melanin makes the skin extremely 
sensitive to UV radiation, increasing the possibility of skin cancer. 
In certain conditions, melanocytes can escape the adjustment made 
	   	  
Figure 2. Agglomerates of melanocytes leads to the formation of nevi. 
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by keratinocytes, leading to the formation of agglomerates called 
nevi (Figure 2a/b). 
These “islands” of melanocytes generally do not represent a 
pathological condition. However, benign nevi are very often 
characterized by a subset of mutations, rendering these cells more 
susceptible to evolve in melanoma malignancy, if crucial genes are 
affected by additional mutations.  
 
Cutaneous melanoma 
 
Melanocytes can undergo tumoral transformation giving rise to the 
malignancy known as Melanoma. Usually, but not always, 
melanoma is a cancer of the skin (cutaneous melanoma), since in this 
tissue is present the highest concentration of melanocytes in the 
body. However, Uveal and Mucosal melanoma represent two 
different categories of melanoma affecting the eyes and mucosal 
tissues such as the oral cavity. Cutaneous melanoma represents an 
aggressive and lethal form of skin cancer whose incidence is rising 
worldwide.  
The growth of a melanoma follows several steps that determine its 
oncogenic potential. Initially, the expansion of the tumor is limited to 
the basal lamina (the so-called Radial Growth Phase, RGP: Figure 3). 
This condition may predispose these cells to evolve in an intra-
epidermis lesion characterized by a local microinvasion into the 
dermis. In this stage a metastatic potential is acquired and iper-
proliferating cells may progress to the Vertical Growth Phase (VGP: 
Vertical Growth Phase) culminating in the formation of proximal or 
distal metastasis (Meier F et al., 1998) (Figure 3). The production of 
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autocrine growth factors and the loss of adhesion receptors 
contribute to the destruction of the intracellular signaling of 
melanocytes.  
Melanomas fall into four major histological subtypes : 
1 . Superficial spreading melanoma (SSM): is the most common 
(approximately 70% of cases) and tends to occur on sun-exposed 
skin. It is characterized by a radial growth phase that lasts from 1 to 
5 years, followed then by a vertical growth phase. 
2 . Lentigo Malignant Melanoma (LMM): represents 5% of 
melanomas. LMM are generally located on the chronically sun 
damaged skin such as the face, head and neck and forearms. It 
originates from a melanoma in situ (lentigo maligna) that can persist 
for many years before moving to a vertical growth phase.	   
3 . Acral Lentiginous Melanoma (ALM) occurs on non-hair-bearing 
surfaces of the body, which may or may not be exposed to sunlight. 
It is also found on mucous membranes. Unlike other forms of 
	  
Figure	  3.	  Radial	  growth	  phase,	  characterize	  primary	  melanoma	  growth	  while	  the	  
vertical	  one	  permits	  the	  dermal	  invasion	  of	  metstatic	  cells.	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melanoma, acral lentiginous melanoma does not appear to be linked 
to sun exposure. It is the most common subtype in people with 
darker skin. 
4 . Nodular Melanoma (NM) is the most aggressive form of 
melanoma. It tends to grow more rapidly in thickness (penetrate the 
skin) than in diameter. Instead of arising from a pre-existing lesion, it 
may appear in a spot where it did not previously exist. It represents 
15-30% of melanomas. 
The first three types start in situ and then sometimes become 
invasive. The NM is considered as a separate category because it is 
invasive from the outset and presents without a significant radial 
growth phase. These characteristics make NM  difficult to detect. 
Most melanomas occur as isolated lesions localized anywhere on the 
skin; invasive ones are much more serious, since they are able to 
penetrate deeper into the skin and may expand to other areas of the 
body: lungs, liver and brain are the favorite sites for metastases. 
In 2002, the American Joint Committee on Cancer (AJCC) has 
proposed a clinical staging system for melanomas based on the 
classical TNM system, considering the thickness of the primary 
tumor (Breslow thickness) and the depth of invasion (Clark level). 
This new system assesses the degree of malignancy according to two 
different parameters:  
A. Clark level of invasion: the skin breaks down into five levels, 
from I to V; the higher the level, the greater the malignancy. 
B. The Breslow thickness: distinguishes four thicknesses measured 
with an ocular micrometer. The higher the thickness in millimeters, 
the greater the degree of malignancy. 
10	  
	  
The choice of a treatment for malignant melanoma depends greatly 
on its stage. 
 
MOLECULAR PATHWAYS INVOLVED IN MELANOMA 
Melanocytic transformation occurs by sequential accumulation of 
genetic and molecular alterations (Miller et al., 2006; Wolchok JD et 
al., 2007). Although the molecular mechanisms underlying 
melanoma development are still largely unknown, many genes and 
metabolic pathways have been described to be altered in melanoma. 
The first step required for melanocytic transformation is a cellular or 
molecular change that is clonally inherited and contributes to the 
potential pathology. Genetic or epigenetic insults generally are the 
main target for an oncogenic activation. The result of such a change 
would be the generation of a melanocytic clone with a growth 
advantage over surrounding cells. Through many years of studies, 
numerous signaling pathways have been characterized to generate or 
contribute to this clonal selection, such as those inducing the cell 
proliferation (proliferative pathways) or bypassing the cell 
senescence (senescence pathway). Moreover, a secondary event, 
required for the progression to the advanced phase of melanoma 
development is to prevent the apoptotic responses (apoptotic 
pathways). More in detail, two of the most frequently dysregulated 
kinase cascades in human cancer are the PI3K/AKT/mTOR and 
RAS/RAF/MEK/ERK pathways (Figure 4)(Liu P et al., 2009; 
Santarpia et al., 2012.).  
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Such pathways represent a key mechanisms of signal transduction, 
regulating the proliferation and survival of cells, in response to the 
stimulation by growth factor receptors. The alteration of downstream 
components of these signaling cascades is frequently altered in 
cancer, thus contributing to tumorigenesis and resistance to 
anticancer therapies (McCubrey JA et al., 2011). Considering their 
importance, the future pharmacology is oriented in generating 
specific drugs, in order to specifically inhibit components of both 
pathways, counteracting the insurgence of mechanisms of resistance. 
 
 
 
Figure4.	  MAPK	  and	  PI3K	  pathways	  represents	  one	  of	  the	  most	  important	  stimolous	  
for	  sustaining	  cancer	  development.	  
	  
MAPK	   and	   PI3K	   pathways	   represents	   one	   of	   the	   most	   important	   stimolous	   for	  
sustaining	  cancer	  development.	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RAS/RAF/MAPK/ERK  
The mitogen activated protein kinase (MAPK) is an extensively 
studied signal transduction pathway in molecular oncology (Fig.  5). 
Being implicated in the control of physiologic processes such as cell 
growth, survival, and invasion, its alteration is involved in the onset 
of a broad spectrum of cancers. MAPK plays a crucial role in 
melanoma development and is the primary subject of molecular 
studies since the discovery of frequent activating mutations of BRAF 
kinase in both melanomas and nevi (Pollock PM et al., 2003; Davies 
H et al., 2002). This signaling initiates at the cell membrane via 
activation of RAS GTPase through different receptor tyrosine 
kinases (RTKs), binding ligand or integrin adhesion to extracellular 
matrix. (Giehl K. et al., 2005; Campbell PM. et al., 2004). The active 
form of RAS (GTP-RAS), efficiently transduces the signal to 
	  
Figure	  5.	  Simplified	  overview	  of	  mammalian	  MAPK	  cascades.	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effector proteins or crosstalks with other signaling pathways, 
modulating cell proliferation, differentiation and survival. (Giehl K. 
et al., 2005). RAF and phosphatidylinositol 3-kinase (PI3K) 
represent the two most important effectors activated by RAS. In 
particular, RAF activation is the sufficient and necessary event to 
continue the MAPK phosphorylative cascade. (Marshall CJ et al., 
1994). A-RAF, B-RAF, and C-RAF are translated from unique genes 
and represent the three isoforms of RAF, differentially expressed in 
cells and tissues, activating the MEK substrates. (Beeram M et al., 
2005). In turn MEK, activates ERK, the downstream effector of the 
MAPK, which releases proliferative or survival signals through 
phosphorylation of a variety of targets: cytoplasmic proteins such as 
ribosomal S6 kinase (p90rsk) or proapoptotic bcl-2 interacting 
mediator of cell death (BIM) (Kohno M. et al., 2006; Panka DJ. et 
al., 2006); cytoskeletal proteins, such as microtubule-associated 
proteins 2 and 4 (MAP 2/4) (Panka DJ. et al., 2006); nuclear 
transcription factors, such as c-MYC, c-FOS, and hypoxia-inducible 
factor-1 alpha. ( Panka DJ. et al., 2006; Sridhar SS. et al., 2005). 
 
 
BRAF and Melanoma 
RAF has been identified as a proto-oncogene many years ago (Rapp 
UR. et al., 1983). In recent years, the identification of activating RAF 
mutations in a large percentage of melanomas has led to considering 
this kinase as a crucial factor for melanoma development. (Davies H. 
et al., 2002). Strikingly, BRAF somatic missense mutations have 
been identified in 66% of malignant melanomas; 80% of these 
mutations consist in a single substitution (V600E)  within the kinase 
domain (Davies H. et al., 2002; Brose MS et al., 2002; Pollock PM et 
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al., 2002). The kinase activity of this mutant is increased over 10-
fold respect to wild-type BRAF. (Davies H et al., 2002). 
Interestingly, further studies revealed that a BRAF-activating 
mutations is also present in up to 82% of benign nevi, suggesting that 
activation of the MAPK pathway is a necessary but not sufficient 
event for melanomagenesis. (Pollock PM et al., 2003). This has also 
been confirmed by experiments in animal models. (Luo C et al., 
2013). 
Considering that BRAF mutation have been observed also in other 
malignancies as papillary thyroid carcinoma (69%) (Cohen Y et al., 
2003; Nikiforova MN. et al., 2003), where they were associated with 
a worse prognosis (Xing M. et al., 2005), whether UV radiation has 
indeed a role in generating BRAF mutation is still a matter of debate 
(Davies H et al., 2002; Albino AP. Et al 1989).  
Although BRAF mutations in nevi are considered a marker of 
melanoma susceptibility, their importance in nevi and melanomas 
remains unclear. Histopathologic analysis suggest that most 
melanomas evolve de novo, without a precursor melanocytic lesion. 
(Bevona C. et al., 2003). 
 
Ras and Melanoma 
RAS is an upstream factor of the MAPK pathway commonly 
deregulated in human cancer (Giehl K. et al., 2005). Activating 
mutations of RAS typically occur at codons 12, 13, or 61, 
maintaining it constitutively active (Barbacid M. et al., 1987). K-
RAS represents the RAS isoform most frequently deregulated in 
many tumors, while N-RAS is the main isoform important in 
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melanoma development (van Elsas A et al., 1995; Ball NJ. Et al., 
1994). RAS mutations contribute to MAPK activation in 15% of 
cutaneous melanomas (Albino AP. Et al., 1989; van’t Veer LJ. Et al., 
1989; Ball NJ. Et al., 1989). A number of in vivo experiments have 
demonstrated the importance of RAS in transforming murine and 
human cells. (Campbell PM. et al., 2004).  In fact, constitutive RAS 
expression targeted to melanocytes in p16ink4a/p19arf-null mice 
leads to cutaneous melanomas with a 60% penetrance (Chin L. et al., 
1997). Moreover, activated RAS is required to maintain these 
melanomas, since its loss leads to the tumor regression (Chin L. et 
al., 1999).  
As it happens with BRAF, the isolated mutation of RAS is also not 
sufficient to initiate melanomas in mice (Powell MB. Et al., 1995; 
Chin L. et al., 1997). Interestingly, tumors with constitutively active 
RAS did not have a high metastatic potential, suggesting that 
additional oncogenes must be involved in generating a metastatic 
phenotype. As mentioned before, RAS mutations in human 
melanoma do not correlate with the degree of sun exposure.  
Since BRAF and N-RAS act as activators of the same pathway, 
BRAF and N-RAS mutations are seldom found together in a same 
melanoma (Curtin JA. Et al., 2005; Davies H. et al., 2002). Rare 
coexistent BRAF (V600E) and N-RAS (Q61R) mutants have been 
described, but the functional significance of this remains unclear 
(Petti C. et al., 2006; Sense M. et al., 2006). 
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Pi3k / Akt 
The phosphatidylinositol-3-kinase (PI3K) pathway is one of the most 
commonly altered pathways in human cancer. (Cully M. et al., 
2006). Class I PI3Ks are heterodimers of a regulatory p85 subunit 
and a catalytic p100 subunit. (Hennessy BT. et al., 2005).  
The main function of PI3K is to phosphorylate the PIP2 
(phosphatidylinositol-4,5-biphosphate) substrates to PIP3 
(phosphatidylinositol-3,4,5-triphosphate) (Robertson GP. Et al.,  
2005)(Fig. 3), to recruit target proteins to the plasma membrane 
(Cully M. et al., 2006) initiating a downstream signaling upon 
stimulation of RTK or G-protein coupled receptors. Akt (protein 
kinase B), is one of the main target of PIP3, with multiple functions 
and regulating a number of cellular processes, and is a commonly 
deregulated kinase in cancer. (Robertson GP. Et al.,  2005) (Fig. 6). 
PIP3 is negatively regulated by PTEN (Phosphatase and tensin 
homolog deleted on chromosome 10) through dephosphorylation of 
PIP3 and is considered an important oncosuppressor. (Hennessy BT. 
	  
Figure	  6.	  AKT	  represents	  one	  of	  the	  main	  target	  of	  the	  PI3K	  pathway	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et al., 2005). The PI3K pathway interacts with many other pathways 
in the cell and controls diverse cellular processes such as 
proliferation, apoptosis, cytoskeletal rearrangement, and tumor cell 
chemoresistance. (Hennessy BT. et al., 2005; Cully M. et al., 2006). 
Interestingly, RAS is able to crosstalk with, and to activate, the PI3K 
signalling. 
Although PI3K represents the second main disregulated pathway in 
melanoma, its genetic alterations are not common. Amplification of 
components of the PI3K complex or PIK3CA mutation (p110 alpha 
subunit of PI3K) are detected in less than 1% of primary melanomas 
and 3% of melanoma metastases (Omholt K et al., 2006). However, 
PI3K inhibitors as Wortmannin and LY294002 exert antitumor 
activity in vitro, inhibiting proliferation and sensitizing cell lines to 
chemotherapy and radiation treatment (Hennessy BT. et al., 2005). 
Akt is closely related to PKA and PKC, consisting of a kinase 
domain, a pleckstrin homology domain, and a regulatory tail 
(Hennessy BT. et al., 2005 Robertson GP et al., 2005). Once active, 
Akt phosphorylates a number of substrates, including MDM2, 
nuclear factor-B, mammalian target of rapamycin (mTOR), bcl-
associated death promoter, human telomerase reverse transcriptase 
(hTERT), and p27, which promote cell survival, proliferation, and 
invasion (Cully M. et al., 2006; Robertson GP et al., 2005). Akt3 is 
the major isoform deregulated in melanoma (Stahl JM et al., 2004). 
Although no activating mutations of Akt3 have been reported in 
primary melanomas, overexpression has been seen (Stahl JM et al., 
2004). 
Targeted decrease of Akt3, either using small interfering RNA or via 
increased activation of PTEN, stimulated apoptosis of melanoma cell 
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lines, indicating a prosurvival function of Akt in melanoma (Stahl 
JM et al., 2004). There have been several studies of Akt expression 
in melanoma. Using IHC, phospho-Akt was detected in 54% of nevi, 
71.3% of primary melanomas, and 71% of melanoma metastases, 
(Slipicevic A et al., 2005) and increased expression was seen in 
severe dysplastic nevi and metastatic melanomas versus benign nevi 
(Stahl JM et al., 2004). Increased phospho-Akt expression in 
melanoma is associated with tumor progression and lower survival 
rate (Meier F et al., 2005). 
PTEN is a tumor suppressor gene that has many functions. It inhibits 
the MAPK pathway, (Slipicevic A et al., 2005) causes cell cycle 
arrest by upregulating p27, (Wu H et al., 2003) increases cell 
migration through dephosphorylation of focal adhesion kinase (FAK) 
and loss of focal adhesion formation, (Slipicevic A et al., 2005) up- 
regulates proapoptotic proteins including caspases and BH3 interact- 
ing domain death agonist, and downregulates antiapoptotic proteins 
such as bcl-2. (Wu H et al., 2003). Ectopic expression of PTEN in 
PTEN-deficient melanoma cells suppresses cell growth, inhibits 
colony formation, and reduces tumorigenicity and metastasis in mice. 
(Wu H et al., 2003) PTEN germline mutations result in Cowden 
disease, an autosomal dominant cancer predisposition syndrome 
(Slipicevic A et al., 2005) in which there is not an increased risk of 
melanomas (Goel VK et al., 2006).  
Loss of tumor suppressor genes on chromosome 10 (including 
PTEN) is involved in 30% to 60% of noninherited melanomas, (Stahl 
JM et al., 2003) and loss of PTEN expression is seen in 30% to 50% 
of melanoma cell lines and 5% to 20% of primary melanomas (Wu H 
et al., 2003). PTEN somatic mutations are seen in melanomas (Wu H 
et al., 2003), where they occur in association with activating 
mutations in BRAF but not N-RAS (Tsao H et al., 2004). This is 
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consistent with the ability of N-RAS to activate both the PI3K and 
MAPK cascades, abrogating the need for specific inactivation of 
PI3K.  
In the recent evaluation of genomic alterations in primary 
melanomas, tumors with BRAF mutations had fewer copies of PTEN 
than those with N-RAS mutations, suggesting that dual activation of 
the PI3K and MAPK pathways are important events in melanoma 
development. (Curtin JA et al., 2005). A recent study suggests that 
epigenetic silencing of PTEN through promoter methylation may 
also be an important means of inactivating this pathway in 
melanoma. (Mirmohammadsadegh A et al., 2006). 
 
 
IGF System 
 
The activation of two intracellular pathways, the Ras-Mek-Erk and 
the PI3K, are stimulated by the same receptor tyrosine Kinase 
located on the cell surface, which can bind several growth factors, 
among which the insulin-like growth factors (IGF-I And IGF-II) 
(Fig. 4) (Siddle K et al., 2001). 
The IGF system plays critical roles in somatic growth in a endocrine 
fashion as well as in the proliferation and differentiation of normal 
and malignant cells in a paracrine-autocrine fashion. (Stewart CE et 
al., 1996). 
The established components of the  IGF system include GH, IGF-I-II 
peptides, type I and II IGF receptors, IGF binding protein (IGFBPs), 
and IGFBP proteases (Fig. 7). 
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GH is the major 
regulator of IGF 
synthesis in the liver. 
GH binding to the 
hepatic GH receptor 
stimulates IGF-I 
synthesis and release 
from the liver, and IGF-
I is transported to the 
main target organs via 
circulation to act as an 
endocrine factor (Butler AA et al., 2001). Circulating IGF-I further 
exerts negative feedback on the somatotropic axis and suppresses the 
release of GH from the pituitary.  
IGF-I/II peptides share approximately 50% homology to insulin. 
They are ubiquitously expressed, highly homologous small peptide 
hormones of approximately 7 kDa molecular mass with multiple 
endocrine and paracrine/autocrine activities (Stewart CE et al., 
1996).  
Most circulating IGF-I is produced by the liver and is responsible for 
growth and development. (Stewart CE et al., 1996). IGFs interact 
with specific cell surface receptors, designated type I and type II IGF 
receptors, and can also interact with the insulin receptor (IR). The 
type I IGF receptor (IGF-IR) is a transmembrane heterotetramer 
consisting of two α-subunits and two β-subunits. (Siddle K et al., 
2001). There is approximately 60% sequence homology between 
IGF-IR and IR (Sjo¨ gren K et al., 1999). IGF-IR, like IR, possesses 
intrinsic tyrosine kinase activity. IGF-II and insulin also bind to IGF-
IR but with 2- to 15-fold and 1000-fold lower affinity, respectively 
(Sjo¨ gren K et al., 1999).  
	  
Figure	  7.	  The	  GH/IGF	  system.	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The type II IGF receptor (IGF-IIR), which is identical to the cation-
independent mannose-6-phosphate receptor, binds IGF-II with 500-
fold increased affinity over IGF-I (Siddle K et al., 2001). IGF-IIR 
does not bind insulin. Most of the biological actions of IGF-II are 
thought to be mediated via IGF-IR (Siddle K et al., 2001). IGF-IIR is 
known to function primarily as a scavenger receptor, regulating the 
internalization and degradation of extracellular IGF-II, thus 
regulating the circulating IGF-II levels.  
IR does not bind IGF-I and IGF-II with high affinity. However, the 
IR isoform and the IR-IGF-IR hybrid bind IGFs as well as insulin. 
IR-A, the IR fetal isoform, binds not only insulin but also IGF-II. 
These IR isoforms and hybrid receptors mediate certain actions of 
IGFs and insulin (Belfiore A et al., 2007). 
 
 
Insulin-Like-Growth-Factor-Binding-Proteins. 
 
A total of seven high-affinity IGF-binding proteins have been 
identified: IGFBP-1 through IGFBP-7 (Walker GE et al., 2004). 
Hepatic IGF-I circulates almost entirely (about 99%) bound to 
IGFBPs.  IGFBP-3, a major IGFBP species in circulation, binds 75 
to 90% of circulating IGF-I in a large ternary complex consisting of 
IGFBP-3, acid-labile subunit (ALS), and IGF. (Phillips LS et al., 
1998). It has been postulated that circulating IGFBP-3 originates in 
the liver and is regulated by GH based upon the presence of a 
putative GH-response element in IGFBP-3 gene. (Phillips LS et al., 
1998; Albiston AL et al., 1995). However, other findings 
demonstrated that GH administration had no effect on the expression 
of hepatic IGFBP-3 mRNA but increased circulating IGFBP-3 in 
human subjects, due to increased formation of the ternary complex 
(Olivecrona H et al., 1999). ALS is produced in the liver as a direct 
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effect of GH. The ALS stabilizes the IGF–IGFBP-3 complex, 
reduces the passage of IGF-I to the extravascular compartment, and 
extends its half-life (Domene´ HM et al., 2005).  
It has become clear that IGFBPs 1–7 have intrinsic biological 
activity (IGF/IGFIR- independent actions) in addition to their actions 
to bind IGFs and sequester the active hormone, thereby reducing IGF 
biological activity (IGF/IGF-IR-dependent actions). (HwaV,OhY et 
al., 1999; Walker GE et al., 2004). 
 
 
Structure of IGFBP-3 
 
IGFBP-3 is a multifunctional protein that is found to play a variety 
of roles in circulation, in the extracellular environment, and inside 
the cell. Mature deglycosylated human IGFBP-3 has a molecular 
mass of 28.7 kDa and is comprised of 264 amino acids. The primary 
structures of mammalian IGFBPs contain three distinct domains of 
roughly equivalent 
sizes, with additional 
critical subdomains or 
functional motifs 
within each major 
domain that 
contribute to their 
diverse actions.  
In addition to the 
structural and 
sequence homology 
among IGFBPs (Fig. 
8), some IGFBPs 
	  
Figure	  8.	  IGFBPs	  share	  a	  common	  structure	  and	  posses	  
an	  high	  variable	  regulatory	  mid-­‐region.	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possess distinctive characteristics such as integrin recognition 
sequences in IGFBP-1 and IGFBP-2; phosphorylation on serine 
residues of IGFBP-1 and IGFBP-3; heparin binding motifs in 
IGFBP-3, -5, and -6; and nuclear localization sequences in IGFBP-3 
and IGFBP-5. These distinctive characteristics could be important 
for the ability of IGFBPs to modulate IGF/IGFIR- dependent actions 
as well as IGF/IGF-IR-independent actions. (Walker GE et al., 
2004). 
 
 
The conserved N-terminal domain 
 
In the mature IGFBP-3 peptide, the N-terminal third of the protein 
contains 87 amino acid residues after the signal peptide. IGFBP-3 
along with all the other members of the IGFBP superfamily (both 
high affinity and low affinity IGF binders) share a common IGFBP 
motif —GCGCCXXC— a conserved N-terminal cysteine rich 
domain (Imai Y et al., 2000).  
IGFBP-3 contains a total of 18 cysteines, 12 of which are located in 
this domain, which leads to the presence of six disulfide bonds 
within this domain. Important IGF-binding residues are known to be 
located within this domain (Buckway CK et al., 2001; Imai Y et al., 
2000). Although no other major functional motifs have been 
identified in the amino-terminal domain, the observation that amino-
terminal proteolytic fragments of IGFBP-3 cause IGF-independent 
inhibition of mitogenesis (Lalou C  et al., 1996; Salahifar H er al., 
2000) implies the presence of another active subdomain in this 
region. This subdomain remains to be identified. 
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The highly variable midregion 
 
The midregion segment of IGFBP-3 contains 95 amino acids. This 
region separates the N-terminal domain from the C-terminal domain 
and shares less than 15% similarity with other IGFBPs. (Firth SM et 
al., 1999). Intriguingly, post-translational modifications 
(glycosylation, phosphorylation) of the IGFBPs have been found in 
the midregion, but not in the N- or C-terminal domains.  
IGFBPs might be differentially targeted to tissues depending upon 
both their primary structure and their posttranslational modifications. 
Thus, glycosylation can affect cell interactions, phosphorylation can 
affect IGF-binding affinity and susceptibility to proteases, and 
proteolysis can affect both IGF/IGF-IR-dependent and IGF/IGF-IR-
independent actions.( Firth SM et al., 2002).  
Three sites of N-linked glycosylation exist in IGFBP-3. 
Carbohydrate increases the core protein size of IGFBP-3 from 29 
kDa to forms estimated to be 40–43 kDa. Of the three potential 
glycosylation sites at Asn89, Asn109, and Asn172, the first two are 
always glycosylated, carrying an estimated 4 kDa and 4.5 kDa of 
carbohydrate, respectively, whereas the third site alternatively 
contains either undetectable or about 5 kDa of carbohydrate, 
accounting for the characteristic doublet form of the protein (Firth 
SM et al., 1999). Other sites of post-translational modification such 
as potential phosphoacceptor sites also reside in this central domain. 
Studies conducted by Yamanaka et al. suggest that IGFBP-3 binds to 
human breast cancer cell surface with typical receptor-ligand 
interaction and the midregion of the IGFBP-3 molecule is 
responsible for the interaction. 
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The conserved C-terminal domain 
 
The C-terminal domain is cysteine rich (six cysteines), with three 
disulfide bonds within this domain. This IGFBP-3 region is also 
important in IGF binding (Devi GR et al., 2000; Spencer EM et al., 
1995). 
Because residues involved in IGF binding are present in both the N-
terminal and C-terminal domains, the findings imply the likely 
existence of an IGF-binding pocket involving both domains. A 
functionally important 18-residue basic motif with heparin-binding 
activity has also been identified at residues 215-232. Apart from 
heparin binding, certain other glycosaminoglycans (Fowlkes JL et 
al., 1996) as well as cell surface proteoglycans (Smith EP et al., 
1994) are bound by this 18-residue basic motif.  
Furthermore, IGFBP-3 as well as IGFBP-3-IGF-I complexes bind 
fibrinogen, fibrin (Campbell PG et al., 1999) and plasminogen 
(Campbell PG et al., 1998), via this binding domain. The basic 
region Lys 228-Arg 232 has also been shown to be essential for 
interactions with the ALS. Additional basic residues that reside 
within this domain interact with the cell surface and matrix, the 
nuclear transporter importin-β and other proteins. Singh et al. have 
also identified a short metal-binding domain in the C-terminal region 
of IGFBP-3 that binds metals and also has intrinsic effects. Although 
in vitro studies do not suggest a potential role for iron in IGF-
independent biological actions of IGFBP-3, they reveal a dose-
dependent effect of iron on IGFBP-3 binding to integrins αv and β1, 
caveolin-1, and transferrin receptor by unmasking of metal-binding 
domain epitopes in the IGFBP-3 molecule (Singh et al., 2004). 
IGFBP-3 binding to transferrin has been shown to be dependent on a 
region in the C-terminal domain (Weinzimer SA et al., 2001). 
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Furthermore, a caveolin-scaffolding domain consensus sequence also 
resides in this region.  
Recent studies have determined three-dimensional structures of 
IGFBPs including IGFBP-1, -2, -4, and -5 using nuclear magnetic 
resonance spectroscopy and x-ray crystallography (Kuang Z et al., 
2007; Kalus W et al., 1998). These structural analyses not only 
confirm the previous findings indicating IGF binding sites in the N- 
and C-terminal domains of IGFBPs but also further reveal that a 
rigid disulfide bond ladder-like structure and the first five amino 
acids in the N-terminal domain are critical for IGF binding and 
masking IGF residues responsible for IGF-I receptor binding.  
The C-terminal domain and the midregion of IGFBPs also contribute 
to inhibiting the interaction between IGF-I and IGF-IR either by 
directly blocking the IGF-IR-binding region of IGF-I or by steric 
hindrance. Thus, these structural data provide an understanding of 
the roles of each domain of IGFBP in enhancing/stabilizing IGF 
binding and modulating IGF binding to IGF-IR.  
Although the structure of IGFBP-3 has not yet been determined, 
IGFBP-3 should have very similar structures in those critical 
domains responsible for cooperative binding to IGF and blocking of 
the IGF-IR binding region of IGF-I. 
 
 
IGF/IGF-IR-Dependent and IGF/IGF-IR Independent Actions of 
IGFBP-3 
 
IGF binding to and subsequent activation of the IGF-IR usually 
results in diverse biological effects in a wide range of cell types, 
including cellular proliferation and differentiation, an increase in 
metabolic activity, and cell survival via antiapoptotic pathways.  
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The IGFBPs are known to modulate the actions of IGFs in the 
circulation as well as the immediate extracellular environment 
(Rajaram S et al., 1997). Interestingly, apart from the ability of 
IGFBPs to inhibit or enhance IGF actions, IGFBPs also exhibit very 
clear, distinct biological effects independent of the IGF/IGF-IR axis. 
These IGF/IGF-IR-independent actions contribute to the diversity of 
biological outcomes due to IGFBPs. IGFBP-3 is a well-documented 
inhibitor of cell growth and/or promoter of apoptosis. Although its 
antiproliferative functions are mainly achieved through the 
attenuation of IGF/IGF-IR interaction (Martin JL et al., 1995), to 
date much light has been shed on the ability of these bioactivities to 
occur via IGF/IGF-IR axis-independent means (Schedlich LJ et al., 
2000; Oh Y et al., 1993). 
The protein inhibitory diffusible factor 45 (now recognized to be 
IGFBP-3) was originally isolated as a novel inhibitory factor, being 
able to inhibit the growth stimulation of chick embryo fibroblasts 
(CEF) in the absence as well as the presence of IGF-I. When bound 
to IGF-I, serum-induced growth stimulation of CEF was attainable, 
suggesting two opposing activities for inhibitory diffusible factor 45 
(Blat C et al., 1989).  
This study was quickly followed by another supporting this 
hypothesis, where fibroblast-growth-factor-stimulated DNA 
synthesis in CEF and mouse embryo fibroblasts was inhibited by 
mouse IGFBP-3 an action independent of IGFs yet attenuated by the 
presence of IGFs (Liu L et al., 1992). Similarly, the overexpression 
of human IGFBP-3 in Balb/c mouse fibroblasts resulted in the 
inhibition of cellular proliferation in the presence/absence of IGFs or 
insulin (Cohen P et al., 1993).  
Although it is clear that IGFBP-3 achieves biological effects 
independent of the IGF/IGF-IR axis, the mechanisms by which these 
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effects are achieved are still not entirely understood. Evidence to 
date suggests the existence of multiple pathways by which IGFBP-3 
elicits its proapoptotic and antiproliferative IGF/IGF-IR-independent 
effects in an array of different cell systems.  
On the other hand, IGFBP-3 also has been shown to stimulate cell 
growth or other cell functions in an IGF independent manner in a 
variety of cell types. Martin et al. (Martin JL et al., 2003) 
demonstrated that IGFBP-3 stimulates growth in MCF-10A human 
breast epithelial cells via increased epidermal growth factor receptor 
phosphorylation and activation of p44/42 and p38MAPKsignaling 
pathways. Similar effect of IGFBP-3 was observed in breast cancer 
cells. Although expression of IGFBP-3 initially inhibited the growth 
of T47D human breast cancer cells, long-term culture of these cells 
resulted in growth stimulation due to an enhanced responsiveness of 
these cells to the proliferative effects of epidermal growth factor 
(Baciuchka M et al., 1998).  
Mitsui Y et al, reported that IGFBP-3 exerts dual effects on human 
umbilical vein endothelial cells, potentiating doxorubicin-induced 
apoptosis but enhancing survival in serum-starved conditions. This 
study further demonstrated that IGFBP-3 antiapoptotic effects were 
mediated through activation of sphingosine kinase and increased 
expression of sphingosine kinase 1. These studies indicate that 
IGFBP-3 enhances cell growth or other cell functions depending on 
specific conditions. However, the underlying molecular mechanisms 
involved in these biological actions of IGFBP-3 are largely 
unknown. 
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RESULTS 
 
Previous work from the laboratory in which I carried out my PhD 
project showed that serum levels of IGFBP-3 are lowered 
significantly in stage-IV melanoma patients (Panasiti V et al., 2011). 
These results are briefly 
summarized in Figure 9. 
Further measurements of 
the IGFBP-3 levels were 
done in sera taken from 
the same patients during 
the follow-up after the 
first diagnosis of 
melanoma.	   Surprisingly 
all the patients with 
progressive disease 
showed a significant 
reduction of IGFBP-3 
concentrations in the 
second sample taken after 
some months, indicating a strong relation between melanoma 
progression and the drop of the protein.  
Moreover in the same work, it was shown that the reduction of 
IGFBP-3 was due to its degradation, probably by a protease secreted 
by the tumour itself, whose amount increased with tumour 
progression.  
In this work, the effect of IGFBP-3 on melanoma progression was 
investigated in vitro and in vivo. The cellular pathways mediating the 
action of the protein were also investigated.  
 
	  
Figure 9. Serum concentration of full-size insulin-
like growth factor binding protein (IGFBP)-3 in 
healthy control subjects (HC) and in patients with 
melanoma staged from 0 to IV. 
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IGFBP-3 in the tissutal microenvironment. 
Considering the previous results, obtained at the systemic level, we 
firstly decided to determine the IGFBP-3 levels in the tissutal 
microenvironment. The aim of this analysis was to asses if the 
progression of primary melanoma to metastatic disease may be 
related to, or influenced by, the presence of IGFBP-3 in the tissues.  
Most of the circulating IGFBP-3 is produced by the liver; however, 
the protein is also secreted by several other inflammatory and 
mesenchymal cell types and by melanocytes themselves.  
	  
Figure	  10.	  (D,G)	  IGFBP-­‐3	  immunostaining	  in	  tissue	  samples	  from	  primary	  melanomas.	  (E,	  H)	  IGFBP-­‐3	  
immunostaining	   in	   tissue	   samples	   from	   metastatic	   melanomas.	   The	   asterisks	   indicate	   positive	  
melanocytes	  nests	  in	  primary	  melanoma.	  The	  arrows	  indicate	  IGFBP-­‐3	  positive	  stromal	  cells.	  Original	  
magnification,	  X100.	  (F,I)	  Graphic	  data	  processing	  for	  total	  (upper	  panel)	  and	  stromal	  (lower	  panel)	  
IGFBP-­‐3	  immunostaining	  score.	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Notably, an inverse correlation has been 
observed between the amount of IGFBP-3 
produced by melanoma tissue and the 
metastatic capacity of the cells (Dar AA  
et al., 2010). To evaluate the presence of 
IGFBP-3 in the immediate environs of the 
tumour, immuno-histochemical analyses 
of primary and metastatic tumour samples 
taken from patients were performed. As 
shown in Fig.10 (D,G), a diffuse 
intracellular IGFBP-3 staining was 
observed in primary melanomas as well as in peri-tumoral stromal 
cells including monocytes/macrophages, lymphocytes, granulocytes 
and fibroblasts. In metastatic tumours IGFBP-3 staining was much 
weaker or absent (Fig.10 E,F,H,I). Previously, we hypothesized that 
IGFBP-3 loss in both blood and tissues could be accounted for 
degradation by tumour-produced 
proteases. This was further 
investigated. Firstly, secretion of 
proteases by cultured primary and 
metastatic melanoma cells lines was 
evaluated by zymography. As shown 
in Fig.11, the primary melanoma line 
WM793 secreted only small amounts 
of a collagenase (metalloprotease-2) 
(MMP-2). By contrast, the metastatic 
cells Me501 produced large amounts 
of proteases, especially MMP-2 and 
metalloprotease-9 (MMP-9). Accordingly, the culture media of 
metastatic, but not primary, cells caused extensive degradation of 
recombinant IGFBP-3 in vitro. (Fig.12). 
	  
Figure 11. Detection of 
MMP-2 and MMP-9 activity 
in the culture media of 
WM793 and Me501 cells by 
zimographic assay. 
	  
Figure 12. Western blot analysis 
showing degradation over time of 
IGFBP-3 by the culture media of 
WM793 and Me501 cells. 
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Secondly, tumour samples taken from patients were immuno-stained 
for both IGFBP-3 and MMP- 9.  
Strikingly, there was an almost perfect inverse correlation between 
the areas of low or no IGFBP-3 staining and those of high MMP-9 
	  
Figure 13. Comparison of the immunohistochemistry for IGFBP-3 (A, C, E) 
and MMP-9 (B, D, F) in sequential sections obtained from primary 
melanomas and dermal metastases. The asterisks mark the melanocytes nests 
while the arrows indicate the stromal tissue. Original magnification X100. 
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staining (Fig.13), suggesting that the enzyme could indeed have a 
role in the degradation of IGFBP-3. 
 
IGFBP-3 inhibits motility and invasion in cell cultures of 
metastatic melanomas.  
To investigate the ability of IGFBP-3 to influence the migratory and 
invasive behavior of metastatic melanoma cells, the effect of the 
protein was tested in vitro on human (Me501) and murine (B16) 
metastatic melanoma cell lines. To this end, scratch-repair and trans-
well migration/invasion tests were performed in the absence and in 
the presence of IGFBP-3.  
For scratch-repair analysis, the metastatic melanoma cell lines were 
grown to confluence in 10% serum. After introduction of the scratch, 
the cells were supplemented with serum-free medium without or 
with added IGFBP-3 (2 ug/ml) and followed for up to 24 hours. As 
the control, the same test was performed on the melanoma primary 
line WM793, which, as expected, had very scarce, if any, migratory 
capacity. 
Strikingly, treatment with IGFPB-3 markedly retarded migration of 
both human and murine metastatic melanoma cells (Fig.14A, middle 
rows). Also, addition of anti-IGFBP-3 antibodies to the culture 
media, to sequester any cell-made IGFBP-3, accelerated scratch 
repair (Fig. 4A, last two rows). Trans-well-migration/invasion assays 
revealed that the invasive capacity of metastatic melanoma cells was 
also strongly impaired by treatment with IGFBP-3, while being 
enhanced by treatment with anti-IGFBP-3 antibodies (Fig.4B). As 
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expected, IGFBP-3 had no effect on the primary melanoma cells 
WM793. 
Importantly, the effect of IGFBP-3 on both migration and invasion 
was independent of cell proliferation. FACS analyses performed on 
semi-confluent cells did not reveal any difference in cell-cycle 
distribution between the IGFBP-3 treated and untreated cells. As 
expected in dearth of serum, both groups underwent cell-cycle arrest 
after a while, but the timing of the arrest was unaffected by IGFBP-3 
treatment (results not shown). 
 
	  
Figure 14B. Trans-well invasion assay with Me501 cell before and after treatment for 48h 
with increasing doses of IGFBP-3 and anti-IGFBP-3 antibodies. 
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Figure 14A. Scratch-test analysis of primary human (WM793) and metastatic 
murine (B16) and human (Me501) melanoma cells, untreated, treated with 2µg/ml of 
IGFBP-3, and treated with 10 µg/ml of anti-IGFBP-3 antibody. The images were 
captured at 0, 6, 24h after incubation. 
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IGFBP-3 signals through the Akt pathway. 
In order to understand the signaling pathways whereby cells respond 
to treatment with IGFBP-3, we analyzed the phosphorylation status 
of relevant kinases belonging to the MAPK and PI3K pathways, 
using pre-cast phosphor-proteome profiler arrays. The human 
metastatic melanoma cell lines were grown to semi-confluence, 
transferred to a serum-free medium and treated with IGFBP-3 for 24 
hours. Fig.15 shows the phosphor-proteome profiles of the Me501 
metastatic lines, treated or not with IGFBP-3.  
	  
	  
	  
Figure 15. Analysis by 
phosphor-proteomic 
arrays of signal-
transduction pathways 
involving in mediating 
IGFBP-3 action. 
Me501 cells before 
(light grey) and after 
(dark grey) treatment 
with IGFBP3. 
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In these cells, treatment with IGFBP-3 produced a drastic 
inactivation of all three Akt isoforms, especially Akt3, with a 
concomitant dephosphorylation of GSK3β and mTOR. The 
activation state of Akt was further analysed at different times of 
treatment with IGFBP-3 (Fig.16). Dephosphorylation was essentially 
complete after 2 hours and remained so for the ensuing 24 hours. The 
overall amount of Akt remained unchanged throughout the 
experiment, indicating that IGFBP-3 had no effect on either the 
expression or the stability of the protein. Overall these results are a 
strong indication that IGFBP-3 significantly affects the AKT-mTOR-
GSK3B axis. 
 
IGFBP-3 acts independently from the IGF1 sequestration.  
Figure 17 briefly summarizes the PI3K 
pathway, an important regulator of AKT 
functions. As shown, the activity of 
AKT is regulated by multiple stimuli 
and its complete network of interactors 
is far more complex (Yong Liao et al., 
2010; Y Lu et al., 2011). However, an 
important event, involved in the 
regulation of AKT is the association 
	  
Figure 17. Brief description of 
the PI3K pathway. 
	  
 
Figure 16. Western blot kinetic 
analysis of the phosphorylation  
of Akt (ser 473) in untreated 
and IGFBP-3 treated Me501 
cells. 
	  
38	  
	  
between IGF1 and its receptor (Hernández-Sánchez C et al., 1995). 
As explained in the Introduction, it is known that one of the 
biological functions of IGFBP-3 is to modulate the access of IGF-1 
to its receptor, thereby modulating the activation state of the PI3K-
AKT pathway. Therefore, it was important to assess whether the 
capacity of IGFBP-3 to dephosphorylate AKT in melanoma cells 
was dependent of IGF-1.  
A number of evidences suggest 
that this is not the case. First, 
the migration/invasion 
experiments were performed in 
the absence of serum, therefore 
in absence of IGF-1. The cells 
themselves did not produce 
IGF-1, as verified by PCR and 
western blot analysis (not shown). Finally, we determined the 
activation state of the IGF1-receptor, by analyzing its 
phosphorylation state. As shown in Fig. 18, in the serum starvation 
conditions employed in 
the migration/invasion 
assays, the basal activity 
of the receptor is rather 
low and remains 
unaffected by treatment 
with IGFBP-3. Control 
experiments in the 
presence of serum showed 
that the inhibition of 
IGF1-R mediated by 
IGFBP3 is in this case 
	  
Figure 18. Analysis of the phoshorylation 
of IGF1-R (Tyr 1135), regulated by the 
IG1 interaction with the receptor. 
	  
Figure 19. Western Blot analysis detecting the 
phosphorylation of kinases involved in the 
regulation of AKT (ser 473) or regulated by AKT. 
39	  
	  
very strong, as expected (Figure 18).  
A kinetic analysis was also performed, whereby the phosphorylation 
state of the IGF-1R was assessed at different times of IGFBP-3 
treatment. As shown in Fig. 19, activation of IGF1-R was poorly 
affected by IGFBP-3 during a treatment of 8 h. Importantly, AKT 
dephosphorylation, which was almost complete already after 1 h, 
was independent of IGF1-R state. In the same experiment, the 
phosphorylation status of several kinases upstream or downstream of 
AKT was also determined. As stated previously, GSK3-beta was 
dephosphorylated upon IGFBP-3 treatment, albeit following a slower 
kinetics than AKT. Dephosphorylation was also observed for mTOR 
2481, a site diagnostic of the activity of mTORC2, an important 
kinase  regulating AKT (Copp J et al., 2009; Xiaoqing Gan et al., 
2011). The fact that mTOR 2481 dephosphorylation follows a slower 
kinetic than AKT suggests that mTORC2 is not involved in AKT 
inhibition.  
IGFBP3 acts through the activation of cellular phosphatases. 
By further analyzing the kinetics of IGFBP-3 
action, it was observed that dephosphorylation 
of AKT was appreciable after only 15 minutes 
of treatment.  
Since we were not able to observe any 
correlation among IGFBP3 treatment and the 
inhibition of upstream activators of AKT (IGF1, 
mTORC2 and PI3K) and considering the speed of the AKT’s 
inhibition, we wondered if this effect could be mediated by an active 
mechanism instead than a passive one. For this reason we 
	  
Figure 20. IGFBP3 
acts on AKT at only 
15 m of treatment. 
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hypothesized that this phenomenon could be mediated by the 
activation of a phosphatase driving AKT dephosphorylation. 
As shown in Figure 17, PTEN, one of the most important tumor 
suppressors of the cell, is a phosphatase that negatively regulates 
AKT (Li L et al., 2007; Song MS et al., 2012). PTEN gene is 
frequently  deleted or mutated in many kind of cancers; however, the 
PTEN protein was absent from our cell lines (not shown), indicating 
that it can not be involved in the IGFBP-3 signaling. 
Besides PTEN, PP1 and PP2A represent the most relevant 
phosphatases of AKT involved in a number of cellular process such 
as the insulin 
signaling, 
apoptosis and 
cellular motility 
(Garcia A et al., 
2003; Galbo T 
et al., 2013; 
Basu S, 2011).  
In order to 
	   	  
Figure 21. Levels of (p) AKT 473 assayed by W.B., after the treatment with Calyculin A 
(left panel) or Okadaic Acid (right panel) added to the medium, 1 h before IGFBP3.  
	  
	  
Figure 22. In the presence of IGF1, the blockage of IGFBP3 
signaling mediated by Okadaic Acid is only partial. The scheme 
summarizes the ipotized mechanisms of IGFBP3’s action  
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understand if these phosphatases could be involved in the regulation 
of AKT we inhibited their activity by using two different 
compounds. Okadaic Acid and Calyculin A have been widely 
employed for their specificity and strength in inhibiting PP1 and 
PP2A activity (Jamie L et al., 2009). Figure 21 shows the results 
obtained by treating Me501 cells (in the absence of serum) for 1 h 
with these compounds, plus IGFBP3. The graphs  clearly show that 
both inhibitors are able to completely block the action of IGFBP3 on 
AKT. This result strongly suggests that the inhibitory action of 
IGFBP-3 on AKT is mediated by the activation of PP1 and PP2A 
phosphatases.  
The experiments with Okadaic Acid were also performed in the 
presence of serum. Figure 22 shows that under these conditions 
IGFBP3 only partially inhibits AKT. This suggests that IGFBP3 
indeed regulates AKT phosphorylation by two different mechanisms; 
an IGF-1 dependent one, which is not affected by phosphatase 
inhibition, and an IGF-1 independent one, which relies on the 
activation of either (or both) PP1 and PP2A phosphatases.  
 
MAPK pathway inhibition in the presence of IGFBP-3 
In the mutational landscape characterizing the oncogenic stimuli that 
sustain a tumor, the hyperactivation of AKT is an important event to 
bypass apoptotic triggers and increase the proliferation rate and 
metastatic potential of cancer cells (Bellacosa A et al., 2005). 
Particularly in melanoma, MAPK activation represents one of the 
most important stimuli in inhibiting apoptosis and triggering cellular 
growth. 
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Accordingly, Me501 
cells have an 
hyperactivated 
MAPK pathway (see 
Fig.15), whose main 
components (ERK) 
are insensitive to 
IGFBP-3 inhibition, 
in agreement with the 
fact that IGFBP-3 
does not affect the 
cell cycle. However, 
since an hyper-active MAPK 
pathway seems to be an 
important hallmark of 
melanomagenesis, we tested 
whether inhibition thereof, in 
addition with IGFBP-3 
treatment, could produce a 
stronger anti-tumoral effect, 
for instance inducing 
apoptosis of the malignant 
cells.  
For this purpose we utilized 
the drug U0126, a potent 
inhibitor of MEK, an 
important component of the 
MAPK pathway (Wu P et al., 
	  
Figure	  23.	  Cell	  cycle	  analysis	  with	  FACS	  sorter	  of	  Me501	  
cells	  treated	  with	  IGFBP3	  and/or	  U0126	  MEK	  Inhibitor.	  
	  
Figure 24. W.B of Me501 cells  treated 
with IGFBP3 and/or U0126 confirmed the 
inhibition of the MAPK signaling. 
	  
Figure 25. Me501 cells, treated with U0126 
and U0126+IGFBP3, showed a deep 
darkening of the cell lysates, suggesting the 
stimulation of the melanogenesis process 
upon the inhibition of the relative pathways. 
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2013).  
Firstly, we analyzed by FACS sorter the cell cycle  of the MEK 
and/or IGFBP-3 treated cells. As mentioned before, IGFBP-3 does 
not have any effect on the cell cycle, while the MEK inhibitor is able 
to block a percentage of cells in the G1 phase, indicating a cell cycle 
arrest (Figure 23). The co-treatment with IGFBP3 and U0126, 
however, did not show any significant additive action on any stage of 
the cell cycle. Moreover, annexin V analysis that allows to detect 
apoptotic cells, also yielded negative results (data not shown). 
Although co-treatment with IGFBP-3 and MEK inhibitor failed to 
induce apoptosis, it had the singular effect of apparently increasing 
the melanine content of the Me501 cells. A darkening of the cell 
lysates was already visually observable upon treatment with U0126, 
and was further increased with the addition of IGFBP-3 (Fig.26).  
Melanin synthesis by both normal and tumoral cells is regulated by 
multiple molecular pathways, including the MAPK and the PI3K 
ones (Mehdi Khaled et al., 2002; H.Y. Park et al., 2009; Shen T et 
al., 2012).  Specifically, the ERK protein negatively regulates 
tyrosinase, the enzyme initiating melanine synthesis. For this reason 
melanoma cells harboring a BRAF mutation, very often show an 
hypopigmentation phenotype caused by reduced levels of tyrosinase 
(Rotolo S et al., 2005). Moreover, the kinase GSK3-beta, which is 
regulated by AKT, also plays an important role in melanogenesis by 
regulating the activity and the levels of tyrosinase. Also in this case 
the hyperactivation of AKT contrasts melanine production by 
repressing GSK3-beta (Mehdi Khaled et al., 2002; Mehdi Khaled et 
al., 2003). 
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IGFBP-3 induces melanocytic differentiation of metastatic 
melanoma cells  
To investigate in greater depth the effect of  IGFBP-3 on 
melanogenesis, we  determined whether treatment of the Me501 cells 
with this protein indeed resulted in activation of the melanine 
synthesis pathway.  
Firstly, we measured the 
melanine content in treated 
and untreated Me501 cells, 
detecting a significant 
increase in the production of 
the pigment (Fig. 26). 
Secondly, we assessed 
whether this depended on 
the activation of tyrosinase, 
the main enzyme 
controlling melanogenesis 
(H.Y. Park et al., 2009). 
This was indeed the case; 
enzymatic assays an 
western blot experiment 
revealed an increase of both 
enzymatic activity (Fig. 27) 
and protein amounts (Fig. 
28).  
This behaviour is in agreement with the fact that one the downstream 
targets of Akt most affected by IGFBP-3 treatment is GSK3β, a 
	  
Figure 26. Me501 cells treated with IGFBP3, 
showed higher levels of melanine content. Analysis 
conducted by measuring the absorbance of 
melanine to the spectrophotometer. 
	  
Figure 27. Me501 cells treated with IGFBP3, 
showed higher Tyrosinase’s activity. Tyrosinase’s 
activity measured by L-DOPA oxidation, by 
measuring the absorbance of DOPA-Quinone to 
the spectrophotometer.  
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factor whose activation by 
dephosphorylation 
triggers melanine 
synthesis and 
differentiation in 
melanocytes (Fig. 28) 
(Mehdi Khaled et al., 
2002; Kazuhisa Takeda et 
al., 2000). 
Besides losing the ability 
of migrate and invade, 
and enhancing melanogenesis, IGFBP-3 treated cells kept in culture 
for a few days acquired also a more dendritic appearance (Fig.29), 
further suggesting that they were steered towards melanocytic 
differentiation.  
 
 
 
	  
	  
	  
Figure	  29.	  Me501	  cells	  treated	  with	  IGFBP3	  (right	  image)	  appear	  
more	  dendritic	  than	  Cnt	  cells	  (left	  image).	  
	  
	  
Figure 28. The levels of Tyrosinase are increased 
upon the 48h treatment with IGFBP3. Gsk3b 
activation by dephosphorilation is an upstream 
event involved in this process. 
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In vivo anti-tumoral effects of IGFBP3 treatment. 
To assess the potential clinical relevance of “in vitro” results, we 
evaluated the anti-tumoral activity of IGFBP-3 in SCID mice 
xenografted s.c. with Me501 human melanoma cell line.  
Three days after tumor injection, mice received subcutaneous 
injections of saline, or 0.37 mg/Kg or 1.87 mg/kg IGFBP-3 three 
times a week (TTW) for three weeks and tumor growth was 
estimated during the follow-up. As illustrated in Table 1 and Fig.30, 
the growth of Me501 tumors in mice treated with IGFBP-3 was 
significantly reduced as compared with control animals, with a dose-
dependent efficacy, and the size of IGFBP-3-treated tumors was 
significantly smaller than control tumors at follow-up (P=0.0005), 
indicating that IGFBP-3 treatment may exert an antineoplastic 
activity in vivo. More in detail, Tumor Volume Inhibition percent 
Table 1. Percentages of tumor weight inhibition (TWI) and percentages of mice tumor free 
in each group number of in Me501 bearing SCID mice treated with IGFBP3 and three 
times a week (TTW) with one day interval for three weeks. For each group standard error 
of the mean (s.e.m.) and complete response ratio (CR) were also reported. The values in 
this table are referred to the day of sacrifice (day 28 after tumor cell injection). Mean 
results are representative of two different experiments (each experiment on at least 8 
mice). Tumor size was measured three times per week with calipers, and volume was 
calculated as described in the “Methods” section.	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(TVI%) in IGFBP-3-treated 
mice was respectively of 
40,33 and 94,61% at 28 
days post-tumor implant. At 
sacrifice, tumor diameter 
was significantly lower (t-
Test p<0.001) in IGFBP-3 
(3± 1,5 and 4.5 ± 2 mm) in 
comparison to saline (9.0 ± 
3 mm) treated mice. 
Moreover, complete 
response (CR) was obtained 
in 2/8 mice treated with the 
lower IGFBP-3 
concentration, in 3/8 mice 
treated with the higher 
IGFBP-3 concentration but 
in none of the saline group 
(Table 1).  
Moreover, tumors from IGFBP3 
treated mice were consistently 
darker than those from untreated 
mice, suggesting upregulation 
of melanine synthesis. Indeed, 
as shown in Fig. 31, tyrosinase 
activity increased in tumor 
tissues from IGFBP-3 treated 
mice, confirming the 
observations made on cultured 
	  
Figure 31. Tyrosinase activity I of 
melanomas excised from untreated and 
IGFBP-3 (high-dose) treated mice was 
measured on tissue homogenates as 
described in Methods for the cultured cells 
	  
Figure 30. Tumour sample derived from each group. 
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melanoma cells. 
Melanoma-bearing SCID mice treated with IGFBP3 did not show 
any signs of systemic toxicity such as weight loss, diarrhea, or hair 
ruffling during the dosing period until sacrifice. Considering the role 
of IGFBP3 in regulating glycaemia, glycemic values were also 
assessed at 4 and 24 hours after the injection of High dose IGFBP3. 
No alteration in glycemic level was observed in IGFBP3 treated 
mice. 
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EXPERIMENTAL PROCEDURES 
 
Immunohistochemistry and immunofluorescence 
The samples tissues was taken from patients affected by cutaneous 
melanoma in the Department of Dermatology of the University 
“Sapienza” of Rome. 
Primary melanoma (20) and dermal metastases (20) were analyzed. 
Immunohistochemistry was performed on 3–5µm thick sections 
obtained from formalin-fixed tissue embedded in paraffin. Antigen 
retrieval was performed using a PT module (pH 6; Thermo Fisher 
Scientific, Fremont, CA, USA).  
The immunohistochemical procedure was performed according to 
alkaline phosphatase method.  
Briefly, rabbit polyclonal anti-MMP-9 antibody (Thermo Scientific, 
RB-9234-P) diluted 1:200 and rabbit polyclonal antibody anti-
IGFBP-3 antibody (AbD, 5345-5109) diluted 1:100 were used as 
primary antibody. After Tris-phosphate buffered saline (TBS) rinse, 
sections were further incubated with labelled polymer in accordance 
with the standard UltraVision AP detection system (Thermo Fisher 
Scientific). After a final TBS rinse, all immunohistochemical 
reactions were visualized by using Liquid Fast-Red Substrate System 
(Thermo Scientific, Runcorn, UK)  as the chromogen and 
hematoxylin as the counterstain. 
The immunohistochemical evaluation was performed independently 
by 2 researchers without knowledge of the patient’s data, using a 
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double-headed microscope. Intra-observer agreement was higher 
than 90%. The number of positive cells was separately counted for 
IGFBP-3 and MMP-9 under a light microscope at 200X 
magnification. For each slide, at least 7-10 microscopic fields were 
randomly chosen. 
A five grade-semi-quantitative scoring system (score 0-4) was 
adopted for the evaluation of IGFBP3 and MMP-9 
immunohistochemical expression. The score was graded according to 
the percentage of stained cells: score 0 was defined as the presence 
of stained positive cells ≤ 5%, score 1, 2 and 3 were defined as the 
presence respectively of  6% to 25%, 26 to 50% and  51%- to 75%  
positive cells and score 4 as the presence of > 75% . 
The immunohistochemical score was evaluated separately for 
melanocytic and stromal cells and expressed as tumour and stromal 
score respectively. A total score was derived for each sample as the 
sum of tumour and stromal score. 
Cell lines and culture conditions 
The Wistar melanoma (WM) cell lines were kindly provided by Dr. 
Meenhard Herlyn, Wistar Institute, Philadelphia, PA. The cell lines 
Me501 were established from metastases obtained from melanoma 
patients surgically resected at the Istituto Nazionale dei Tumori, 
Milan, Italy. All melanoma cell lines were seeded in 3-cm Petri 
dishes (2 × 105 or 4 × 105 per dish) in RPMI 1640 supplemented 
with 100IU/mL penicillin, 100µg/mL streptomycin (Life 
Technologies, Gaithersburg, MD), and 2mmol/L glutamine (Life 
Technologies) with 10% FCS in a 5% CO2 environment at 37°C. 
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Phospho-Proteome Profiler 
The phospho-proteome profiler array was performed by utilizing the 
RD System “Human Phospho-Kinase Array Kit”. 
 
Western blot analysis 
Cells were grown to 80% confluence and then harvested on ice using 
cell lysis buffer (20mM tris, pH 7.5, 150mM NaCl, 1% Triton X, 1X 
protease and phosphatase inhibitor mixture (Roche Applied Science). 
Cells were dounce-homogenized and centrifuged at 10,000 Xg for 
10min. The supernatant was quantitated using Bradford assay; 30µg 
of each lysate was run out on 12.5% SDS-polyacrylamide on under 
reducing conditions and transferred onto 0.2-µm nitrocellulose. The 
membranes were probed with antibodies: (p)Akt Ser 473, total Akt 
(p)Gsk3β Ser 9, (p) Tyr 1135 IGF1-R, total IGF1R, (p) Thr202/204 
ERK1/2, total mTOR, (Cell Signaling), β-Tubulin (Sigma-Aldrich), 
(p) Ser 2448 mTOR, (p) Ser 2481 mTOR (Millipore). 
Visualization of signal was performed by using the ECL system 
(Pierce). 
 
Pharmacological Inhibitors 
Okadaic Acid (at 60nM - 100nM) and Calyculin A (at 15 nM) 
phosphatase inhibitor, was taken from Santa Cruz Biotechnology. 
Both inhibitors were added to the medium 1 hour before adding 
2µg/ml IGFBP3. 
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U0126 was taken from Calbiochem and added at 10 µM, 1 hour 
before adding 2µg/ml IGFBP3. 
Gelatin substrate zymography 
For gelatin zymography, 20 µl of serum-free medium were separated 
on 10% SDS-polyacrylamide gels containing 1mg/ml bovine gelatin 
(Sigma, Deisenhofen, Germany) under non-reducing condition. 
Following electrophoresis, the gels were washed twice for 30 
minutes in 2.5% Triton X-100 to remove SDS. After equilibration in 
enzyme substrate buffer (50mM Tris-HCl, pH 7.5; 150mM NaCl; 
5mM CaCl2, the gels were incubated in the same buffer overnight at 
37°C. They were then stained with Coomassie Blue R 250 and 
destained in water. 
IGFBP-3 protease assays 
To assay for protease activity in the culture media of melanoma cells, 
20pmol of full-length, glycosylated IGFBP-3 was mixed with 20µl of 
serum-free medium from Me501 cells and the samples were 
incubated at 37°C for 96h and then subjected to SDS-PAGE under 
reducing conditions. IGFBP-3 proteolysis was analyzed by Western 
blot. 
Scratch-Wound Assay 
To evaluate the effect of IGFBP-3 on cell motility and migration, a 
scratch-wound assay was done on WM793, Me501 and B16 cells. 
Monolayer cells were scraped with a pipette tip to generate a scratch 
wound after cells reached confluence. The wounded surface was 
washed with 1×PBS and incubated in RPMI without fetal bovine 
serum in the presence or in the absence of recombinant IGFBP3 
(ABd serotec). Cell migration into the wound was monitored by 
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phase microscopy using an Axiovert 200M microscope with digital 
camera (Carl Zeiss, Thornwood, NY), taking pictures at 2, 4, 6, 24, 
and 48 h. The images were captured by AxioVision 4.0 software 
(Carl Zeiss). The closure of the initial gap area was assessed by 
calculating the difference between the initial and the remaining 
wound area at each time point. 
 
BD biocoat matrigel invasion assay 
BD matrigel chambers, stored at -20°C, were kept at room 
temperature for 1h, after which 500µl of DMEM was added to the 
wells. The inserts were then transferred to the medium-containing 
wells. DMEM (500µl) was added to the inserts and kept at 37°C in 
an incubator with 5% CO2 for equilibration. After 2h, the medium in 
the inserts was aspirated and inserts were placed into the wells 
containing DMEM and 5% FBS which acts as a chemo-attractant for 
the cells to migrate. Overall, 50000 cells in 500µl of DMEM were 
added to the inserts. The plates were incubated for 22h in a CO2 
incubator at 37°C. The chamber inserts were then stained using the 
Diff-Quick staining kit (Dade-Behring) according to the 
manufacturer's instructions. Finally, the membranes were separated 
with a sterile scalpel and observed using a light microscope. The 
number of cells that had passed through the membranes were 
counted as a measure of their migration potential. 
 
In Vivo Tumor Growth Analyses 
Female CB.17 SCID/SCID mice aged 4–5 weeks (Harlan; 
Correzzana, Milan, Italy) were kept under specific pathogen-free 
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conditions and fed ad libitum. Mice were housed in micro-isolator 
cages, and all food, water, and bedding were autoclaved prior to use. 
Each mouse was injected subcutaneously in the right flank with 0.5 × 
106 human melanoma Me501 cells derived from metastatic lesions 
that had been resuspended in 0.2 mL of RPMI-1640 containing 10% 
FCS. Three days after tumor injection IGFBP3 resuspended in 
normal saline was administered subcutaneously three times a week 
with one day interval, at the doses of either 0.37 or 1.87 mg/kg. 
Tumor dimensions were measured three times per week with 
calipers. Tumor weight was estimated according to Geran et al. using 
the following formula: tumor weight (mg) = length (mm) × 
width2(mm)/2. 
At least 8 mice were used for each treatment group. Data are 
expressed as the mean value of tumor weight with 95% confidence 
intervals. Mice were monitored for the duration of the in vivo 
experiments for body weight, hair ruffling, and the presence of 
diarrhea. All mice were killed at the end of the experiments, 28 days 
after the injection of the human tumor cells. 
 
Ethic Statement 
Animal experiment were conducted in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The protocol was 
approved by the Committee on the Ethics of Animal Experiments  of 
Istituto Superiore di Sanità, Italy . All surgery was performed under 
sodium pentobarbital anesthesia, and all efforts were made to 
minimize suffering. 
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Statistical analysis 
In order to establish which variables were statistically related to high 
IGFBP-3 serum level in melanoma patients, data were entered into a 
Microsoft Excel spreadsheet and analyzed by the ANOVA test; a P 
value <0.05 was considered statistically significant (Table 1). 
A receiver operating characteristic (ROC) curve analysis was used to 
find an average value of metastatic volume, IGFBP-3 serum level 
and IGF1/IGFBP-3 molar ratio, in order to dichotomize the patients 
into two subgroups, according to the cut off obtained. 
Overall survival (OS) was calculated as the time lasting from the first 
sample withdrawal to the date of death or last follow-up; the OS 
curves were compared using the Kaplan-Meier method in order to 
correlate the survival time with IGFBP-3 serum level and 
IGF1/IGFBP-3 ratio. 
Statistical analysis for immunohystochemical results was conducted 
with the Mann Whitney U test. To assess significant correlations, the 
Spearman correlation coefficient was calculated.  
A t test analysis was performed to compare the mean tumor volumes 
in xenografted SCID mice. 
P values <0.05 were regarded as statistically significant. 
Statistical analyses was performed through MedCalc® version 
12.1.4.0 (Schoonjans F et al., 1995). 
 
 
56	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57	  
	  
DISCUSSION 
In this study we show that IGFBP-3 has a remarkable anti-tumoral 
activity on malignant melanoma, both in vitro and in vivo.  
Previous clinical observations revealed that IGFBP-3 serum levels of 
melanoma patients were highly correlated with disease stage and 
progression. Indeed, stage IV patients underwent a significant loss of 
circulating IGFBP-3, whose extent was a strong predictor of survival 
time (Panasiti V et al., 2011). In this work it is shown that IGFBP-3 
loss is also appreciable in the tissutal microenvironment, where the 
progression to the metastatic phase of melanoma was accompanied 
by a reduction in IGFBP-3 immunostaining both in the stromal cells 
surrounding the tumour and in tumour cells themselves.  
This may suggest that melanomas have an active role in destroying 
IGFBP-3, and indeed many tumors are known to produce proteases. 
Accordingly, metastatic, but not primary, melanoma cells secreted 
large amounts of a MMPs, mostly MMP-9. These results agree with 
a former study reporting that blood serum from IV-stage melanoma 
patients was uniquely able to degrade IGFBP-3 in vitro (Panasiti V et 
al., 2011). It is possible, therefore, that melanomas ingrain a self-
sustaining loop, destroying IGFBP-3 as they grow and becoming as a 
consequence ever more aggressive. However, the alternative 
hypothesis that melanomas inhibit tissutal, or even hepatic, 
production of IGFBP-3 cannot yet be discounted and is currently 
being tested. 
In vitro assays on cell cultures revealed that IGFBP-3 affects the 
ability of cells to migrate and invade rather than that to proliferate. In 
fact, the highly motile and invasive behavior of the two cell lines of 
metastatic tumors analyzed (Me501 and the murine line B16) was 
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strongly inhibited by treatment with human recombinant IGFBP-3. 
IGFBP-3-induced proliferation arrest and apoptosis induction were 
described by other investigators (Gribben L et al., 2012; Mehta HH 
et al., 2011), but to the best of our knowledge inhibition of cell 
motility and invasiveness has not been reported previously.  
Phosphor-proteome profiling of certain signal transduction pathways 
involved in tumoral transformation revealed that the metastatic cells 
treated with IGFBP-3 turned off AKT. AKT inactivation caused the 
concomitant dephosphorylation of its primary target GSK3β. That 
GSK-3β in particular may be a mediator of the anti-metastatic effect 
of IGFBP-3 is suggested by the fact that IGFBP-3-treated cells 
showed a tendency to revert to a more differentiated melanocytic 
phenotype, as indicated by the increase of both tyrosinase activity 
and melanine content. In fact, GSK3β is known to promote melanine 
synthesis and melanocyte differentiation (Mehdi Khaled et al., 2002; 
Kazuhisa Takeda et al., 2000).  
The molecular mechanism whereby IGFBP-3 promotes AKT 
dephosphorylation remains to be deciphered; however, the data 
presented here point to an important involvement of cellular 
phosphatises PP1 and PP2A. In fact, treatment of melanoma cells 
with a specific inhibitor of these phosphatases was able to abolish 
IGFBP-3-triggered AKT dephosphorylation.  
This surmise is in agreement with the observation that the inhibitory 
effect of IGFBP-3 on AKT appears to be independent of IGF-1. This 
is borne out by the facts that the motility/invasiveness assays were 
performed in the absence of IGF-1, that the cells under study did not 
produce IGF-1 and had very low levels of (p)IGF-1 receptor that 
IGFBP3 treatment is not able to further deregulate.  Therefore, 
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IGFBP-3 apparently exerts its anti-migratory/invasive effect 
independently of the IGF1R/PI3K pathway. 
The anti-tumoral effect of IGFBP-3 was also investigated in vivo 
using a murine model, namely SCID mice which were inoculated 
with human melanoma (Me501) cells. Tumor growth was strongly 
inhibited already upon administering low doses of IGFBP-3, and 
completely arrested in  2 out of  8 cases already at lower doses, and 
in 3 out of 8 cases at higher doses. In agreement with in vitro 
observations on cultured cells, tumours from IGFBP-3 treated mice 
appeared darker and had higher melanine content and tyrosinase 
activity, suggesting that also in vivo IGFBP-3 directed tumoral cells 
to revert towards a more melanocytic phenotype.  
Importantly, IGFBP-3 did not produce evident toxic effect even at 
the higher doses, nor had detectable negative impact on glucose 
metabolism. 
Altogether, the results presented here suggest that IGFBP-3 is a 
potentially interesting anti-tumoral agent, all the more because it is a 
physiological factor that is not expected to have major adverse 
effects when given therapeutically. At the least, it may qualify for a 
valid adjuvant therapy in melanoma (and perhaps other cancers) 
during treatment with conventional anti-tumoral drugs. 
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